Research Journal of Pharmacology
ISSN: Online 1993-6019ISSN: Print 1815-9362
Abstract
Heart failure (HF) is a complex and debilitating condition affecting millions globally, characterized by impaired cardiac function and significant morbidity and mortality. Effective pharmacotherapy has been central to HF management, targeting mechanisms such as neurohormonal dysregulation, fluid retention and cardiac contractility. Over the past decade, novel pharmacological agents have emerged, offering improved outcomes for patients, particularly those with heart failure with reduced ejection fraction (HFrEF). Search Strategy were describe the databases used (e.g., PubMed, Cochrane Library). Outline the specific keywords and Medical Subject Headings (MeSH) terms employed for the search. This systematic review synthesizes recent advancements in HF pharmacotherapy, focusing on sodium‐glucose co‐transporter 2 (SGLT2) inhibitors, angiotensin receptor‐neprilysin inhibitors (ARNIs), soluble guanylate cyclase simulators and selective cardiac myosin activators. A comprehensive literature search was conducted using PubMed to identify relevant randomized controlled trials, systematic reviews and meta‐analyses published between 2013 and 2023. Studies were selected based on their evaluation of the efficacy and safety of these therapies in HF management. The findings reveal significant benefits associated with newer agents, including reduced cardiovascular mortality, lower hospitalization rates and improved quality of life. Despite these advancements, challenges such as cost, accessibility and adherence to guideline‐directed medical therapy persist. In conclusion, pharmacotherapy for HF has evolved significantly, with novel agents complementing traditional therapies and offering new hope for improved patient outcomes. Future research should focus on personalized medicine approaches and strategies to enhance the implementation of these therapies in clinical practice.
How to cite this article:
J. Gayathri and K.P. Selvarajan Chettiar. Advances in Pharmacotherapy for Heart Failure: A Systematic Review.
DOI: https://doi.org/10.36478/10.36478/makrjp.2024.3.38.45
URL: https://www.makhillpublications.co/view-article/1815-9362/10.36478/makrjp.2024.3.38.45